Printer Friendly

PURE BIOSCIENCE REPORTS 2ND FISCAL QTR NET LOSS OF 1,553,700.

PURE Bioscience (OTCBB: PURE), San Diego, Calif., has reported revenues for the second fiscal quarter ended January 31, 2008 of approximately $152,400 compared with revenues of $168,800 in the second quarter of the previous year. The company reported a net loss of approximately $(1,553,700), or $(0.06) per share for the quarter compared with a loss of $(1,008,112), or $(0.04) per share in second fiscal quarter of the previous year. Revenues for the six month period ended January 31, 2008 were approximately $247,800, as compared with revenues of $196,500 in the same period of the previous year. The company reported a net loss of approximately $(2,562,400), or $(0.10) per share, compared with a loss of $(1,875,400), or $(0.08) per share, in the previous period.

"For the third consecutive quarter our revenues increased, said Michael L. Krall, president and CEO of PURE Bioscience. More importantly, discussions and negotiations with key new partners and distributors for our SDC technology have progressed substantially, and we expect to finalize a number of contracts in the near term across multiple industries.

"Additionally, as our current distributors and partners obtain national, state and international approvals and ready their marketing and sales initiatives, we expect to see the results of their marketing efforts as they continue to establish our SDC technology in the market place. We are seeing a marked increase in potential partner companies, both in the United States and internationally, who are recognizing the capabilities and the potential of our SDC technology within their particular markets. "

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area).

For more information, visit http://www.purebio.com or call 212/554-5462.
COPYRIGHT 2008 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Financial Reports
Article Type:Financial report
Geographic Code:1USA
Date:Apr 1, 2008
Words:399
Previous Article:CANTEL MEDICAL REPORTS 18% INCREASE IN SALES FOR 2ND QTR 2008.
Next Article:IDERA REPORTS 4TH QTR NET LOSS OF $4.5 MILLION.
Topics:


Related Articles
Insurance company software.
PURE BIOSCIENCE HAS 3RD QTR FISCAL NET LOSS OF $2,466,400.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters